WEKO3
アイテム
{"_buckets": {"deposit": "b3d125e0-4bbf-4217-862e-66db772e9ff7"}, "_deposit": {"created_by": 1, "id": "533", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "533"}, "status": "published"}, "_oai": {"id": "oai:showa.repo.nii.ac.jp:00000533", "sets": ["68"]}, "author_link": ["2695", "2697", "2694", "2698", "2699", "2696"], "item_10002_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "347", "bibliographicPageStart": "337", "bibliographicVolumeNumber": "28", "bibliographic_titles": [{"bibliographic_title": "The Showa University journal of medical sciences"}]}]}, "item_10002_description_6": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The aim of the present study was to assess the non-inferiority of low-dose benralizumab relative to high-dose benralizumab as a treatment option for uncontrolled eosinophilic asthma through a meta-analysis of efficacy and safety in randomized controlled trials (RCTs). PubMed, the Cochrane Library Database, and Scopus were searched to identify relevant articles. Outcome measures were a change in the Asthma Control Questionnaire-6 (ACQ-6) score and the exacerbation rate. In addition, the meta-analysis assessed the incidence of adverse events, injection site reactions, and pyrexia or influenza-like illness. Two RCTs with two doses of benralizumab (20 and 100mg) and a placebo for the treatment of uncontrolled eosinophilic asthma met the criteria and were included in the present study. Non-inferiority of low-dose (20mg) versus high-dose (100mg) benralizumab was shown for the change in ACQ-6 score, exacerbation rate, and the incidence of adverse events, injection site reactions, and pyrexia or influenza-like illness. Although not significant, the incidence of pyrexia or influenza-like illness was lower in patients treated with low-dose benralizumab. These results suggest that low-dose (20mg) benralizumab is effective for symptom control and reduction of exacerbation rate in uncontrolled eosinophilic asthma, with lower treatment costs.", "subitem_description_type": "Abstract"}]}, "item_10002_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Showa University Society"}]}, "item_10002_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.15369/sujms.28.337", "subitem_relation_type_select": "DOI"}}]}, "item_10002_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10781651", "subitem_source_identifier_type": "NCID"}]}, "item_10002_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0915-6380 ", "subitem_source_identifier_type": "ISSN"}]}, "item_10002_text_26": {"attribute_name": "アイテムタイプ", "attribute_value_mlt": [{"subitem_text_value": "学内発行雑誌 / Departmental Bulletin Paper"}]}, "item_10002_text_27": {"attribute_name": "POS_INDEX", "attribute_value_mlt": [{"subitem_text_value": "学内発行雑誌/The Showa University journal of medical sciences/Vol.28(2016)/No.4"}]}, "item_10002_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "ANDO, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "2694", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TANAKA, Akihiko"}], "nameIdentifiers": [{"nameIdentifier": "2695", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YOKOE, Takuya"}], "nameIdentifiers": [{"nameIdentifier": "2696", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OHNISHI, Tsukasa"}], "nameIdentifiers": [{"nameIdentifier": "2697", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "INOUE, Shin"}], "nameIdentifiers": [{"nameIdentifier": "2698", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SAGARA, Hironori"}], "nameIdentifiers": [{"nameIdentifier": "2699", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-07-26"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "S28_337.pdf", "filesize": [{"value": "456.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 456200.0, "url": {"label": "S28_337.pdf", "url": "https://showa.repo.nii.ac.jp/record/533/files/S28_337.pdf"}, "version_id": "9d40f2cc-eab6-44b3-b3f0-4da6ffa75100"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Meta-analysis of Low-versus High-dose Benralizumab in Adults with Uncontrolled Eosinophilic Asthma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Meta-analysis of Low-versus High-dose Benralizumab in Adults with Uncontrolled Eosinophilic Asthma", "subitem_title_language": "en"}]}, "item_type_id": "10002", "owner": "1", "path": ["68"], "permalink_uri": "https://showa.repo.nii.ac.jp/records/533", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-12-01"}, "publish_date": "2017-12-01", "publish_status": "0", "recid": "533", "relation": {}, "relation_version_is_last": true, "title": ["Meta-analysis of Low-versus High-dose Benralizumab in Adults with Uncontrolled Eosinophilic Asthma"], "weko_shared_id": 1}
Meta-analysis of Low-versus High-dose Benralizumab in Adults with Uncontrolled Eosinophilic Asthma
https://showa.repo.nii.ac.jp/records/533
https://showa.repo.nii.ac.jp/records/53309789ef6-e343-4107-aed5-dd9cdc4100ff
名前 / ファイル | ライセンス | アクション |
---|---|---|
S28_337.pdf (456.2 kB)
|
|
Item type | 学内発行雑誌 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-12-01 | |||||
タイトル | ||||||
タイトル | Meta-analysis of Low-versus High-dose Benralizumab in Adults with Uncontrolled Eosinophilic Asthma | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ | departmental bulletin paper | |||||
著者 |
ANDO, Koichi
× ANDO, Koichi× TANAKA, Akihiko× YOKOE, Takuya× OHNISHI, Tsukasa× INOUE, Shin× SAGARA, Hironori |
|||||
書誌情報 |
The Showa University journal of medical sciences 巻 28, 号 4, p. 337-347, 発行日 2016-12 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The aim of the present study was to assess the non-inferiority of low-dose benralizumab relative to high-dose benralizumab as a treatment option for uncontrolled eosinophilic asthma through a meta-analysis of efficacy and safety in randomized controlled trials (RCTs). PubMed, the Cochrane Library Database, and Scopus were searched to identify relevant articles. Outcome measures were a change in the Asthma Control Questionnaire-6 (ACQ-6) score and the exacerbation rate. In addition, the meta-analysis assessed the incidence of adverse events, injection site reactions, and pyrexia or influenza-like illness. Two RCTs with two doses of benralizumab (20 and 100mg) and a placebo for the treatment of uncontrolled eosinophilic asthma met the criteria and were included in the present study. Non-inferiority of low-dose (20mg) versus high-dose (100mg) benralizumab was shown for the change in ACQ-6 score, exacerbation rate, and the incidence of adverse events, injection site reactions, and pyrexia or influenza-like illness. Although not significant, the incidence of pyrexia or influenza-like illness was lower in patients treated with low-dose benralizumab. These results suggest that low-dose (20mg) benralizumab is effective for symptom control and reduction of exacerbation rate in uncontrolled eosinophilic asthma, with lower treatment costs. | |||||
DOI | ||||||
関連識別子 | 10.15369/sujms.28.337 | |||||
出版者 | ||||||
出版者 | Showa University Society | |||||
ISSN | ||||||
収録物識別子 | 0915-6380 | |||||
著者版フラグ | ||||||
出版タイプ | VoR |